Treatment Reality of Tension Band Wiring and Locked Plate Fixation of the Olecranon

September 25, 2024 updated by: Prof. Dr. med. J. Christoph Katthagen, University Hospital Muenster

Treatment Reality of Tension Band Wiring and Locked Plate Fixation of the Olecranon - Analysis of Complications, Risk Profiles and Trends

The incidence of the olecranon fracture (OF) in adults is around 12 per 100,000 inhabitants per year.1 The anatomical shape of the proximal ulna is largely responsible for the stabilization of the humeroulnar joint and reconstruction is therefore obligatory, but often challenging. Surgical treatment of the olecranon fracture is performed using tension band wiring (TBW) or locking plate fixation (LPF) osteosynthesis. It is not yet clear, which procedure is superior for a specific patient. In future, an individualized and objectified assessment of expected general and fracture-specific complications should enable the treatment to be individually adapted to the patient's risk profile. This shall prevent complications, unnecessary treatments, and treatment costs. In the project presented here, the reality of care for surgically treated patients with olecranon fractures will be analyzed using routine data collected by the BARMER health insurance fund.

The aim of the study is to analyze differences in the outcome of patients with an olecranon fracture treated with TBW compared to LPF and to identify independent risk factors for unfavorable course.

Study Overview

Study Type

Observational

Enrollment (Actual)

15705

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

All adult patients with an age of 18 years and older with an inpatient treated OF (ICD S52.01) treated with LPF or TBW between 01/2011 and 09/2023 will be included to the evaluations. Patients were grouped by age (i.e. 18-44 years, 45 - 69 years, ≥ 70 years). Younger patients (<70 years) and older patients (≥ 70 years) will be analyzed in separate studies.

Description

Inclusion Criteria:

  • Inpatient coded diagnosis of olecranon fracture (ICD S52.01)

Exclusion Criteria:

  • Incomplete basic information
  • Incomplete insurance status within two years before index
  • Previous treatment of olecranon fracture
  • Unclear treatment of olecranon fracture
  • Age < 18 years
  • Coded polytrauma
  • Bone tumors/ bone metastasis
  • Both sides injured or missing information of surgery side

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Locking Plate fixation for simple fractured OFs (sLPF)
Patients allocated to this treatment group received a locking plate fixation after the first coded diagnosis of simple fractured OF.
OPS 5-793.k7
Locking Plate fixation for multi-fragmented OFs (LPF)
Patients allocated to this treatment group received a locking plate fixation after after the first coded diagnosis of multi-fragmented OF.
OPS 5-794.k7
Tension band wiring for simple fractured OFs (sTBW)
Patients allocated to this treatment group received a tension band wiring fixation after the first coded diagnosis of simple fractured OF.
OPS 5-793.27
Tension band wiring for multi-fragmented OFs (TBW)
Patients allocated to this treatment group received a tension band wiring fixation after the first coded diagnosis of multi-fragmented OF.
OPS 5-794.17

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Revision
Time Frame: up to 5 years
Time from surgery to revision defined above.
up to 5 years
Implant removal (only)
Time Frame: up to 5 years
  • Time from surgery to implant removal
  • Within first 3 months after surgery, an implant removal will also considered as a surgical complication
  • No SC is allowed to occur within 3 months and on the same day
up to 5 years
Surgical complications (surgical complications)
Time Frame: up to 5 years
Time from surgery of olecranon fracture to surgical complications, with death being considered as a competing risk event.
up to 5 years
In-hospital surgical complication rate (IH-SC)
Time Frame: through hospital stay, an average of 10 days
surgical complication after surgery during index hospitalization (yes/no)
through hospital stay, an average of 10 days
In-hospital implant-associated complications (IH-IAC)
Time Frame: through hospital stay, an average of 10 days
In-hospital implant-associated complications after surgery during index hospitalization
through hospital stay, an average of 10 days
In-hospital non-implant associated complications (IH-non-IAC)
Time Frame: through hospital stay, an average of 10 days
Non-in-hospital implant-associated complications after surgery during index hospitalizationi
through hospital stay, an average of 10 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall survival (OS)
Time Frame: up to 5 years
  • Time from surgery to death of any cause.
  • Death will be determined using the coded death as the reason for withdrawal in the BARMER database. In addition, all inpatient cases will be reviewed during follow-up, to determine whether death was reported as the reason for discharge.
up to 5 years
30-day mortality
Time Frame: 30 days
  • Death from any cause within first day after surgery (yes/no)
  • All patients with shorter follow-up time are excluded
30 days
Major adverse events (MAE)
Time Frame: up to 5 years
Time from surgery to resuscitation, cardiac arrest, myocardial infarction, stroke, acute renal failure, acute liver failure, acute respiratory distress syndrome, sepsis or death from any case.
up to 5 years
Thromboembolic events
Time Frame: up to five years
Time from surgery to a thromboembolic event or death of any cause.
up to five years
Minor outpatient complication
Time Frame: up to five years
Time from discharge to minor outpatient complications, with death being considered as a competing risk event.
up to five years
Length of hospital stay during index
Time Frame: an average of 10 days
Days of hospitalization (from admission to last discharge with index case series)
an average of 10 days
Charges during index
Time Frame: an average of 10 days
Sum of charges of all cases of the index case series
an average of 10 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2011

Primary Completion (Actual)

September 30, 2023

Study Completion (Actual)

December 31, 2023

Study Registration Dates

First Submitted

September 17, 2024

First Submitted That Met QC Criteria

September 25, 2024

First Posted (Actual)

September 27, 2024

Study Record Updates

Last Update Posted (Actual)

September 27, 2024

Last Update Submitted That Met QC Criteria

September 25, 2024

Last Verified

September 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The authors confirm that the data utilized in this study cannot be made available in the manuscript, the supplemental files, or in a public repository due to German data protection laws ('Bundesdatenschutzgesetz', BDSG). They are stored on a server of the BARMER Institute for Health System Research, to facilitate replication of the results. In general, access to data of statutory health insurance funds for research purposes is possible only under the conditions defined in German Social Law (SGB V § 287).

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe